Tanya Babich, Pontus Naucler, John Karlsson Valik, Christian G Giske, Natividad Benito, Ruben Cardona, Alba Rivera, Celine Pulcini, Manal Abdel Fattah, Justine Haquin, Alasdair Macgowan, Sally Grier, Julie Gibbs, Bibiana Chazan, Anna Yanovskay, Ronen Ben Ami, Michal Landes, Lior Nesher, Adi Zaidman-Shimshovitz, Kate McCarthy, David L Paterson, Evelina Tacconelli, Michael Buhl, Susanna Mauer, Jesus Rodriguez-Bano, Isabel Morales, Antonio Oliver, Enrique Ruiz De Gopegui, Angela Cano, Isabel Machuca, Monica Gozalo-Marguello, Luis Martinez Martinez, Eva M Gonzalez-Barbera, Iris Gomez Alfaro, Miguel Salavert, Bojana Beovic, Andreja Saje, Manica Mueller-Premru, Leonardo Pagani, Virginie Vitrat, Diamantis Kofteridis, Maria Zacharioudaki, Sofia Maraki, Yulia Weissman, Mical Paul, Yaakov Dickstein, Leonard Leibovici, Dafna Yahav
BACKGROUND: The optimal antibiotic regimen for Pseudomonas aeruginosa bacteremia is controversial. Although β-lactam monotherapy is common, data to guide the choice between antibiotics are scarce. We aimed to compare ceftazidime, carbapenems, and piperacillin-tazobactam as definitive monotherapy. METHODS: A multinational retrospective study (9 countries, 25 centers) including 767 hospitalized patients with P. aeruginosa bacteremia treated with β-lactam monotherapy during 2009-2015...
May 23, 2020: Clinical Infectious Diseases